A proposed metabolic strategy for monitoring disease progression in Alzheimer's disease
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
A specific, sensitive and essentially non‐invasive assay to diagnose and monitor Alzheimer's disease (AD) would be valuable to both clinicians and medical researchers. The aim of this study was to perform a metabonomic statistical analysis on plasma fingerprints. Objectives were to investigate novel biomarkers indicative of AD, to consider the role of bile acids as AD biomarkers and to consider whether mild cognitive impairment (MCI) is a separate disease from AD. Samples were analysed by ultraperformance liquid chromatography–MS and resulting data sets were interpreted using soft‐independent modelling of class analogy statistical analysis methods. PCA models did not show any grouping of subjects by disease state. Partial least‐squares discriminant analysis (PLS‐DS) models yielded class separation for AD. However, as with earlier studies, model validation revealed a predictive power of Q2<0.5 and indicating their unsuitability for predicting disease state. Three bile acids were extracted from the data and quantified, up‐regulation was observed for MCI and AD patients. PLS‐DA did not support MCI being considered as a separate disease from AD with MCI patient metabolic profiles being significantly closer to AD patients than controls. This study suggested that further investigation into the lipid fraction of the metabolome may yield useful biomarkers for AD and metabolomic profiles could be used to predict disease state in a clinical setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting bile‐acid signalling for metabolic diseases
Thomas, C., Pellicciari, R., Pruzanski, M., Auwerx, J., & Schoonjans, K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2619 · Cited by 1,422
Visser, P. J., Scheltens, P., Verhey, F. R. J., Schmand, B., Launer, L. J., Jolles, J., & Jonker, C. (1999) · Journal of Neurology · doi:10.1007/s004150050387 · Cited by 319
Cited by
MahmoudianDehkordi, S., Arnold, M., Nho, K., Ahmad, S., Jia, W., Xie, G., Louie, G., Kueider‐Paisley, A., Moseley, M. A., Thompson, J. W., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.07.217 · Cited by 706
Understanding the role of gut microbiome–host metabolic signal disruption in health and disease
Holmes, E., Li, J. V., Athanasiou, T., Ashrafian, H., & Nicholson, J. K. (2011) · Trends in Microbiology · doi:10.1016/j.tim.2011.05.006 · Cited by 541
Chemometrics in metabolomics—A review in human disease diagnosis
Madsen, R., Lundstedt, T., & Trygg, J. (2010) · Analytica Chimica Acta · doi:10.1016/j.aca.2009.11.042 · Cited by 557
Nho, K., Kueider‐Paisley, A., MahmoudianDehkordi, S., Arnold, M., Risacher, S. L., Louie, G., Blach, C., Baillie, R., Han, X., Kastenmüller, G., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.08.012 · Cited by 343
Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease
Whiley, L., Sen, A., Heaton, J., Proitsi, P., García-Gómez, D., Leung, R., Smith, N., Thambisetty, M., Kloszewska, I., Mecocci, P., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.08.001 · Cited by 340
Self-citation
Metadata
- Authors
- Greenberg, N., Grassano, A., Thambisetty, M., Lovestone, S., & Legido‐Quigley, C.
- Venue
- ELECTROPHORESIS
- Publisher
- Wiley
- Published
- 2009-04
- Volume
- 30
- Issue
- 7
- Pages
- 1235-1239
- ISSN
- 0173-0835 (ISSN-L)
- 1522-2683
- OpenAlex
- W1987892912
- Cited by
- 89
- References
- 2
- FWCI
- 2.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A proposed metabolic strategy for monitoring disease progression in Alzheimer's disease. https://app.cochat.ai/papers/10.1002/elps.200800589
- The paper
- Greenberg, N., Grassano, A., Thambisetty, M., Lovestone, S., & Legido‐Quigley, C. (2009). A proposed metabolic strategy for monitoring disease progression in Alzheimer's disease. ELECTROPHORESIS. https://doi.org/10.1002/elps.200800589
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.